CGEM

NASDAQ 已收盘

Cullinan Therapeutics

9.07 USD
▲+0.06+0.67%
盘后 8.89 -1.98%
2026-11-19
市值
$577.15M
市盈率
—
EPS
-3.43
股息率
—
52 周区间
8.23 – 23.19
成交量
999.86K
Beta
-0.06
目标价
34.70
52W 低 8.2352W 高 23.19
价格走势

公司简介

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysp...